Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Inside the FDA Ebola Edition: Frontrunners Merck & Co., Inc. (MRK), GlaxoSmithKline PLC (ADR) (GSK)

Page 1 of 5

Introduction

Back on May 12, 2015, the Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee released a briefing document detailing the process for licensure of Ebola vaccines and the required demonstration of effectiveness. This Market Exclusive Inside the FDA report aims to go inside this briefing document, break it down, and from there extrapolate based on the companies furthest along in developing an effective vaccine, according to the guidelines set out by the FDA itself.

Ebola is one of the world’s deadliest viruses in terms of mortality rate, though thankfully it is not a pandemic. It kills up to 90% of those who contract it, and there is no currently available cure or vaccination. The most recent outbreak began in 2013 in Guinea, West Africa. While it is now considered under control, the outbreak continues to hit certain populations in Africa, and there have been just shy of 30,000 reported cases of infection to date.

pharmacist, medical, retail, worker, team, young, staff, lab, chemistry, business, drug, chemist, adult, teamwork, drugstore, service,

wavebreakmedia/Shutterstock.com

This has sparked a government-private industry scramble to develop and manufacture a vaccine that can be used to prevent further outbreaks. Two companies are at the forefront of this scramble, and their vaccine candidates have emerged as frontrunners in the race to commercialization. Here’s a look at the companies in question, and the drugs on which each is working, reflected through the perspective of the FDA panel.

The Ebola Virus

First, let’s take a look at the virus itself and the disease it causes. The image below is an electron micrograph of the Ebola virus virion, which is the form of the virus before it infects a host cell.

EbolaImage 1 source

There are actually five currently identified and recognized types of Ebola virus, all categorized within the viral genus Ebolavirus. The five types (referred to as members in the scientific space) are each named after their original region of location:

1. Bundibugyo ebolavirus

2. Reston ebolavirus

3. Sudan ebolavirus

4. Taï Forest ebolavirus (originally Côte d’Ivoire ebolavirus)

5. Zaire ebolavirus

The final one, the Zaire ebolavirus (here on in referred to as ZEBOV) is by far the deadliest, and is responsible for the most breakouts across the 40-year period for which we have known about the virus. It’s the one responsible for the latest outbreak.

Page 1 of 5

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!